Opportunities and Challenges in Stem Cell Therapy in Cardiovascular Diseases: Position Standing in 2022

Overview

Journal Saudi Pharm J

Specialty Pharmacy

Date 2022 Oct 17

PMID 36249945

Authors

Shabnur Mahmud

Safaet Alam

Nazim Uddin Emon

Umme Habiba Boby

Kamruzzaman

Firoj Ahmed

A S M Monjur-Al-Hossain

Afroza Tahamina

Sajib Rudra

Marzina Ajrin

Affiliations

Soon will be listed here.

Abstract

This study intends to evaluate the development, importance, pre-clinical and clinical study evaluation of stem cell therapy for the treatment of cardiovascular disease. Cardiovascular disease is one of the main causes of fatality in the whole world. Though there are great progressions in the pharmacological and other interventional treatment options, heart diseases remain a common disorder that causes long-term warnings. Recent accession promotes the symptoms and slows down the adverse effects regarding cardiac remodelling. But they cannot locate the problems of immutable loss of cardiac tissues. In this case, stem cell treatment holds a promising challenge. Stem cells are the cells that are capable of differentiating into many cells according to their needs. So, it is assumed that these cells can distinguish into many cells and if these cells can be individualized into cardiac cells then they can be used to replace the damaged tissues of the heart. There is some abridgment in this therapy, none the less stem cell therapy remains a hopeful destination in the treatment of heart disease.

Citing Articles

A Comprehensive Review on Potential In Silico Screened Herbal Bioactive Compounds and Host Targets in the Cardiovascular Disease Therapy.

Zarenezhad E, Hadi A, Nournia E, Rostamnia S, Ghasemian A Biomed Res Int. 2024; 2024:2023620.

PMID: 39502274 PMC: 11537750. DOI: 10.1155/2024/2023620.

Revolutionizing medicine: recent developments and future prospects in stem-cell therapy.

Hussen B, Hussen B, Taheri M, Yashooa R, Abdullah G, Abdullah S Int J Surg. 2024; 110(12):8002-8024.

PMID: 39497543 PMC: 11634165. DOI: 10.1097/JS9.0000000000002109.

To Repair a Broken Heart: Stem Cells in Ischemic Heart Disease.

Stougiannou T, Christodoulou K, Dimarakis I, Mikroulis D, Karangelis D Curr Issues Mol Biol. 2024; 46(3):2181-2208.

PMID: 38534757 PMC: 10969169. DOI: 10.3390/cimb46030141.

Application and challenges of stem cells in cardiovascular aging.

Yuan H, Chang L, Fan W, Liu X, Li Q, Tian C Regen Ther. 2023; 25:1-9.

PMID: 38108044 PMC: 10724492. DOI: 10.1016/j.reth.2023.11.009.

Human Stem Cells for Cardiac Disease Modeling and Preclinical and Clinical Applications-Are We on the Road to Success?.

Correia C, Ferreira A, Fernandes M, Silva B, Esteves F, Leitao H Cells. 2023; 12(13).

PMID: 37443761 PMC: 10341347. DOI: 10.3390/cells12131727.

References

Jiang Z, Liu G, Meng F, Wang W, Hao P, Xiang Y . Paracrine effects of mesenchymal stem cells on the activation of keratocytes. Br J Ophthalmol. 2017; 101(11):1583-1590. DOI: 10.1136/bjophthalmol-2016-310012. View

Segers V, Lee R . Stem-cell therapy for cardiac disease. Nature. 2008; 451(7181):937-42. DOI: 10.1038/nature06800. View

Brickwedel J, Gulbins H, Reichenspurner H . Long-term follow-up after autologous skeletal myoblast transplantation in ischaemic heart disease. Interact Cardiovasc Thorac Surg. 2013; 18(1):61-6. PMC: 3867044. DOI: 10.1093/icvts/ivt434. View

Gnecchi M, Zhang Z, Ni A, Dzau V . Paracrine mechanisms in adult stem cell signaling and therapy. Circ Res. 2008; 103(11):1204-19. PMC: 2667788. DOI: 10.1161/CIRCRESAHA.108.176826. View

Schraufstatter I, Discipio R, Khaldoyanidi S . Mesenchymal stem cells and their microenvironment. Front Biosci (Landmark Ed). 2011; 16(6):2271-88. DOI: 10.2741/3853. View

Karantalis V, Hare J . Use of mesenchymal stem cells for therapy of cardiac disease. Circ Res. 2015; 116(8):1413-30. PMC: 4429294. DOI: 10.1161/CIRCRESAHA.116.303614. View

Ott H, Matthiesen T, Brechtken J, Grindle S, Goh S, Nelson W . The adult human heart as a source for stem cells: repair strategies with embryonic-like progenitor cells. Nat Clin Pract Cardiovasc Med. 2007; 4 Suppl 1:S27-39. DOI: 10.1038/ncpcardio0771. View

Almeida S, Skelton R, Adigopula S, Ardehali R . Arrhythmia in stem cell transplantation. Card Electrophysiol Clin. 2015; 7(2):357-70. PMC: 4441953. DOI: 10.1016/j.ccep.2015.03.012. View

Quijada P, Salunga H, Hariharan N, Cubillo J, El-Sayed F, Moshref M . Cardiac Stem Cell Hybrids Enhance Myocardial Repair. Circ Res. 2015; 117(8):695-706. PMC: 4583815. DOI: 10.1161/CIRCRESAHA.115.306838. View

10.

Tang Y, Zhao Q, Zhang Y, Cheng L, Liu M, Shi J . Autologous mesenchymal stem cell transplantation induce VEGF and neovascularization in ischemic myocardium. Regul Pept. 2003; 117(1):3-10. DOI: 10.1016/j.regpep.2003.09.005. View

11.

Messina E, De Angelis L, Frati G, Morrone S, Chimenti S, Fiordaliso F . Isolation and expansion of adult cardiac stem cells from human and murine heart. Circ Res. 2004; 95(9):911-21. DOI: 10.1161/01.RES.0000147315.71699.51. View

12.

Bearzi C, Rota M, Hosoda T, Tillmanns J, Nascimbene A, De Angelis A . Human cardiac stem cells. Proc Natl Acad Sci U S A. 2007; 104(35):14068-73. PMC: 1955818. DOI: 10.1073/pnas.0706760104. View

13.

Poole J, Quyyumi A . Progenitor Cell Therapy to Treat Acute Myocardial Infarction: The Promise of High-Dose Autologous CD34(+) Bone Marrow Mononuclear Cells. Stem Cells Int. 2013; 2013:658480. PMC: 3655659. DOI: 10.1155/2013/658480. View

14.

Golpanian S, Wolf A, Hatzistergos K, Hare J . Rebuilding the Damaged Heart: Mesenchymal Stem Cells, Cell-Based Therapy, and Engineered Heart Tissue. Physiol Rev. 2016; 96(3):1127-68. PMC: 6345247. DOI: 10.1152/physrev.00019.2015. View

15.

Senyo S, Steinhauser M, Pizzimenti C, Yang V, Cai L, Wang M . Mammalian heart renewal by pre-existing cardiomyocytes. Nature. 2012; 493(7432):433-6. PMC: 3548046. DOI: 10.1038/nature11682. View

16.

Zhang C, Huang T, Wu B, He W, Liu D . Stem cells in cancer therapy: opportunities and challenges. Oncotarget. 2017; 8(43):75756-75766. PMC: 5650462. DOI: 10.18632/oncotarget.20798. View

17.

Lu B, Malcuit C, Wang S, Girman S, Francis P, Lemieux L . Long-term safety and function of RPE from human embryonic stem cells in preclinical models of macular degeneration. Stem Cells. 2009; 27(9):2126-35. DOI: 10.1002/stem.149. View

18.

Meyer G, Wollert K, Lotz J, Pirr J, Rager U, Lippolt P . Intracoronary bone marrow cell transfer after myocardial infarction: 5-year follow-up from the randomized-controlled BOOST trial. Eur Heart J. 2009; 30(24):2978-84. DOI: 10.1093/eurheartj/ehp374. View

19.

Hamamoto H, Gorman 3rd J, Ryan L, Hinmon R, Martens T, Schuster M . Allogeneic mesenchymal precursor cell therapy to limit remodeling after myocardial infarction: the effect of cell dosage. Ann Thorac Surg. 2009; 87(3):794-801. PMC: 3021253. DOI: 10.1016/j.athoracsur.2008.11.057. View

20.

Rigol M, Solanes N, Farre J, Roura S, Roque M, Berruezo A . Effects of adipose tissue-derived stem cell therapy after myocardial infarction: impact of the route of administration. J Card Fail. 2010; 16(4):357-66. DOI: 10.1016/j.cardfail.2009.12.006. View